Cepheid Posts 24 Percent Revenue Growth for Q1 | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Cepheid reported after the close of the market Thursday that its first-quarter revenues increased 24 percent with strong sales coming from both its systems and reagents and disposables.

The Sunnyvale, Calif.-based molecular diagnostics firm reported total revenues of $48 million for the three-month period ended March 31 compared to $38.8 million for the first quarter of 2009. Its results beat analysts' consensus estimate for the quarter of $45.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.